Navigation Links
New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
Date:6/24/2014

Singapore, 24 June 2014Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth. The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukaemia immunotherapy .

Leukaemia is characterized by the accumulation of cancer cells originating from blood cells, in the blood or bone marrow. Current treatments for leukaemia largely involve chemotherapy to eradicate all cancer cells, followed by stem cell transplants to restore healthy blood cells in the patients.

In a recent study reported in the Journal of Experimental Medicine (JEM) online, the team co-led by Dr Lucia Mori and Prof Gennaro De Libero identified a new class of lipids, methyl-lysophosphatidic acids (mLPA), which accumulate in leukaemia cells. Following which, the team identified a specific group of immune cells, described as mLPA-specific T-cells that are capable of recognising the mLPA in the leukaemia cells. The detection triggers an immune response that activates the T cells to kill the leukaemia cells and limits cancer progression. The efficacy of the T cells in killing leukaemia cells was also demonstrated in a mouse model of human leukaemia.

Thus far, only proteins in cancer cells have been known to activate T cells. This study is a pioneer in its discovery of mLPA, and the specific T cells which can identify lipids expressed by cancer cells. Unlike proteins, lipids in cancer cells do not differ between individuals, indicating that the recognition of mLPA by mLPA-specific T-cells happens in all leukaemia patients. This new mode of cancer cell recognition suggests that the T-cells can potentially be harnessed for a leukaemia immunotherapy that is effective in all patients.

"The identification of mLPA and its role in activating specific T cells is novel. This knowledge not only sheds light on future leukaemia studies, but also complements ongoing leukaemia immunotherapy studies focusing on proteins in cancer cells," said Dr Lucia Mori, Principal Investigator at SIgN. "Current treatments run the risk of failure due to re-growth of residual leukaemia cells that survive after stem cell transplants. T-cell immunotherapy may serve as a complementary treatment for more effective and safer therapeutic approach towards leukaemia."

Professor Laurent Renia, Acting Executive Director of SIgN, said, "At SIgN, we study how the human immune system protects us naturally from infections. We engage in promising disease-specific research projects that ultimately pave the way for the development of treatments and drugs which can better combat these diseases. A pertinent example will be this study; this mode of immune recognition of leukaemia cells is an insightful discovery that will create new opportunities for immunotherapy to improve the lives of leukaemia patients."


'/>"/>

Contact: Tan Yun Yun
tan_yun_yun@a-star.edu.sg
65-682-66273
Biomedical Sciences Institutes (BMSI)
Source:Eurekalert

Related medicine news :

1. Newly discovered brown fat cells hold possibilities for treating diabetes, obesity
2. Lipids help to fight leukemia
3. Leukemia drug found to stimulate immunity against many cancer types
4. One in 4 children with leukemia not taking maintenance medication, study shows
5. Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
6. Tiny mutation triggers drug resistance for patients with one type of leukemia
7. Major discovery on the mechanism of drug resistance in leukemia and other cancers
8. New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
9. Novel target found for chemotherapy-resistant leukemia cells
10. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
11. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Utah (PRWEB) , ... February 28, 2017 , ... ... held Overl.ai Inc., a healthcare automation intelligence company based in New York. , ... is ensuring the provider’s workflow remains unaltered. Those two fundamental reasons are the ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and overall body strength, which often leads to a host of health issues, ... of the American Geriatrics Society discovered that good overall muscle strength in ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... Morristown, New Jersey (PRWEB) , ... February 27, 2017 , ... ... the highest cancer rates, among all types and genders. And the need for advanced ... led by RWJ and its top-rated cancer care program, in collaboration with their non-profit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 28, 2017 ... Research and Markets has announced the ... 2025" report to their offering. The global ... of USD 239.8 billion by 2025. The rising prevalence of lifestyle-induced ... over the forecast period. Advancements in recombinant molecular technologies and high ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 27, ... company developing proprietary therapeutics for the treatment of ... drug delivery platform, today announced that the U.S. ... initial review of the ropinirole implant Investigational New ... hold the initiation of the clinical study pending ...
Breaking Medicine Technology: